Waldenstrom Macroglobulinemia — Trials

Waldenstrom Macroglobulinemia — Trials · CancerIndex

Clinical trials

Registered studies

308 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 59
Recruiting: 26
Ph III recruiting: 2
Growth YoY: —
Industry share: 39%
Top sponsor: Christian Buske
Termination share: 30.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (53)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07548450	Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)(MPOWER)	not yet recruiting	Phase 2	25	University of UtahOTHER	1	Sep 24, 2026	clinicaltrials
NCT07791498	Teclistamab In Waldenstrom's Macroglobulinemia	not yet recruiting	Phase 2	24	Massachusetts General HospitalOTHER	1	Sep 1, 2026	clinicaltrials